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Abstract
Background: Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. 
Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have 
been validated in digestive oncology. The aim of this study was to draw up an ordered list of potential surrogate 
endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists. Secondary 
objective was to obtain their opinion on surrogacy and quality of life (QoL).
Methods: In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and 
methodologists involved in the conduct of cancer clinical trials. In the first questionnaire, panellists were asked to 
choose the most important characteristics defining a surrogate among six proposals, to give advantages and 
drawbacks of the surrogates, and to answer questions about their validation and use. Then they had to suggest 
potential surrogate endpoints for OS in each of the following tumour sites: oesophagus, stomach, liver, pancreas, biliary 
tract, lymphoma, colon, rectum, and anus. They finally gave their opinion on QoL as surrogate endpoint. In the second 
questionnaire, they had to classify the previously proposed candidate surrogates from the most (position #1) to the 
least relevant in their opinion.
Frequency at which the endpoints were chosen as first, second or third most relevant surrogates was calculated and 
served as final ranking.
Results: Response rate was 30% (24/80) in the first round and 20% (16/80) in the second one. Participants highlighted 
key points concerning surrogacy. In particular, they reminded that a surrogate endpoint is expected to predict clinical 
benefit in a well-defined therapeutic situation. Half of them thought it was not relevant to study QoL as surrogate for 
OS.
DFS, in the neoadjuvant settings or early stages, and PFS, in the non operable or metastatic settings, were ranked first, 
with a frequency of more than 69% in 20 out of 22 settings. PFS was proposed in association with QoL in metastatic 
primary liver and stomach cancers (both 81%). This composite endpoint was ranked second in metastatic oesophageal 
(69%), colorectal (56%) and anal (56%) cancers, whereas QoL alone was also suggested in most metastatic situations.
Other endpoints frequently suggested were R0 resection in the neoadjuvant settings (oesophagus (69%), stomach 
(56%), pancreas (75%) and biliary tract (63%)) and response. An unexpected endpoint was metastatic PFS in non 
operable oesophageal (31%) and pancreatic (44%) cancers. Quality and results of surgical procedures like sphincter 
preservation were also cited as eligible surrogate endpoints in rectal (19%) and anal (50% in case of localized disease) 
cancers. Except for alpha-FP kinetic in hepatocellular carcinoma (13%) and CA19-9 decline (6%) in pancreas, few 
endpoints based on biological or tumour markers were proposed.
Conclusion: The overall results should help prioritise the endpoints to be statistically evaluated as surrogate for OS, so 
that trialists and clinicians can rely on endpoints that ensure relevant clinical benefit to the patient.Methy et al. BMC Cancer 2010, 10:277
http://www.biomedcentral.com/1471-2407/10/277
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Background
In cancer clinical trials, overall survival (OS), defined as
time from randomization to death from any cause, is con-
sidered as the gold standard endpoint for the demonstra-
t i o n  o f  c l i n i c a l  b e n e f i t  [ 1 ] .  I t  i s  a n  o b j e c t i v e ,
unambiguously defined endpoint with clear clinical
meaning to the patient. However, the evaluation of OS
may require extended follow-up and the effect of the
experimental treatment on OS may be confounded by
effective subsequent therapies, including cross-over to
the experimental treatment for patients initially allocated
to control therapy [2].
The use of an earlier alternative endpoint would allow
to shorten clinical trials and to evaluate treatment effect
with better specificity. Such an endpoint can be used as
definitive measure of treatment clinical efficacy instead of
OS if it is surrogate  for OS. A surrogate endpoint is
defined as a biomarker "expected to predict clinical bene-
fit (or harm or lack of benefit or harm) based on epidemi-
ologic, therapeutic, pathophysiologic, or other scientific
evidence" [3]. In addition to the biologic plausibility of the
relationship between the surrogate and OS, evaluation of
a surrogate endpoint requires statistical analyses using
data from completed phase III clinical trials to demon-
strate how reliably and in which proportion an effect on
the surrogate can predict the effect on OS [4,5].
In digestive oncology, few variables have undergone
evaluation process [5-7]. To date, only disease-free sur-
vival (DFS) for the adjuvant treatment of colon cancer
[8,9] and progression-free survival (PFS) in the metastatic
setting [10,11] have been fully validated as surrogates for
OS for the evaluation of first line chemotherapies. It is
therefore of interest to identify putative surrogates, so
that they can get priority statistical evaluation.
The main objective of this study was to draw up a list of
potential surrogate endpoints for OS in digestive oncol-
ogy trials, by way of a survey among clinicians and meth-
odologists involved in the conduct of clinical trials.
Secondary objective was to obtain their opinion on par-
ticular points concerning surrogacy and quality of life
(QoL).
Methods
We polled a panel of French clinicians and methodolo-
gists involved in cancer trials by means of self adminis-
tered sequential questionnaires in 2007 and 2008. The
panel was composed of 14 methodologists or biostatisti-
cians, and 66 clinicians working in the field of cancer clin-
ical trials (gastroenterologists, oncologists, surgeons,
radiotherapists). Clinicians were members of the scien-
tific committee of the Fédération Francophone de Can-
cérologie Digestive (FFCD), to whom the protocol of the
survey was presented during a scientific council sitting.
The design of our survey was based on Delphi tech-
nique guidelines [12], which is a consensus method.
However, in our survey, while participants were asked to
classify the endpoints they proposed, they did not re-
evaluate their opinion according to responses of other
panellists and formal consensus was not searched for.
Two rounds were planned (Figure 1). In each round the
questionnaire was sent by postal way and by e-mail.
Reminder letter (e-mail) was sent about two months after
the postal delivery. The second questionnaire was sent to
all panellists, whether they had answered the first one or
not.
First Round. The first questionnaire was composed of
t h r e e  p a rt s  ( s e e  a d d i t i o n a l  f i l e  1 :  S u rv ey  q u e s t i o n n a i r e
No1):
- Part I: panellists were asked 1) to choose the most
important characteristics defining a surrogate among six
proposals; 2) to give advantages and drawbacks of the
surrogates and 3) to answer questions about their valida-
tion and use in digestive oncology;
- Part II: they were asked to mention, if any, endpoints
they thought worthwhile to be evaluated as surrogate for
OS in each of the following tumour sites, according to the
* Correspondence: nicolas.methy@u-bourgogne.fr
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stage of the disease (e.g. locally advanced, metastatic):
oesophagus, stomach, liver, pancreas, biliary tract, lym-
phoma, colon, rectum, and anus;
- Part III: they were asked to give their opinion about
quality of life (QoL) as candidate surrogate.
At the end of the questionnaire, they were free to add
comments.
Second Round (see additional file 2: Survey question-
naire No2):
A feedback report summarized the respondents'
answers to parts I and III items and accompanied the sec-
ond questionnaire. The second questionnaire tabulated
all the surrogate endpoints proposed in part II of the first
questionnaire. In each situation, participants were asked
to classify the previously proposed surrogates, from the
most promising (position #1) to the last promising in
their opinion.
Descriptive statistics (histograms with frequencies)
were used to summarize the responses of the first round
(parts I and III). For each proposed surrogate, the fre-
quency (%) at which it was chosen in the three first posi-
tions was calculated and served as numerical
classification for the final ranking.
Results
First round
It was initiated in June 2007 and closed in September
2007. The response rate was 30% (24/80). Respondents
were composed of 14 gastroenterologists, three oncolo-
gists, one surgeon, one radiotherapist, four methodolo-
gists and one biostatistician.
Part 1
The most frequently chosen sentence among the six pro-
posed to characterize a surrogate endpoint was the one
that defined a surrogate as "an intermediate variable, reli-
ably and reproducibly measurable, which allows to pre-
dict the effect of treatment on the clinical endpoint" [13]
(chosen by 19 participants out of 24). Definition of sur-
rogacy in terms of the equivalence of hypothesis tests for
the treatment effects (Prentice's definition [14]) was the
less chosen (2 out of 24) (Figure 2).
Participants underlined several advantages and risks or
limitations in using surrogate endpoints. On the one
hand, they said that surrogates may allow to reduce trial
duration, the number of patients and/or the cost of the
studies, and to avoid the confounding effect of subse-
quent effective therapies. On the other hand, they ques-
tioned their validity and warned from the risk of
erroneous conclusions. They also set limits to generaliza-
tion of the results to other settings than the one used for
validation (Table 1).
Twenty two out of 24 participants thought it was neces-
sary to perform specific validation studies before using a
surrogate endpoint, and fifteen stated to have knowledge
of such studies. They quoted Buyse et al. 2000 [15] and
Johnson et al. 2006 [16], for advanced colorectal cancer,
and Sargent et al. 2005 [8] in colorectal cancer adjuvant
setting. They also quoted the ongoing meta-analysis
GASTRIC [17] which is aimed at evaluating DFS and PFS
in stomach cancers. The large majority of participants
wrote they were ready to rely on other endpoints than OS
(19/24) after having verified their validation as surrogates
for OS (21/24) (Figure 3).
Part 2
Endpoints proposed for surrogacy evaluation were resitu-
ated in the second questionnaire (see Second round para-
graph and additional file 3: Propositions and rankings of
potential surrogate endpoints for overall survival). To the
question "Are there situations in which you think looking
for surrogate endpoints is useless?" some respondents
answered bad prognostic cancers such as pancreas and
oesophagus metastatic cancers, whereas others thought it
was always useful.
Part 3
Two thirds of the participants thought that QoL was both
a prognostic factor and the secondary endpoint in diges-
tive oncology clinical trials, whereas only half of them
thought it would be relevant to evaluate its surrogacy
(Figure 4).
At the end of the questionnaire, free remarks con-
cerned QoL. It was said to be too much difficult to be
quantified and too much treatment period dependent.
QoL was said to be relevant for bad prognostic cancers,
for which a benefit of QoL could be preferred to a sur-
vival gain. Other participants stated that QoL was a rele-
vant outcome on its own merit.
Second round
It was initiated in July 2008 and closed in October 2008.
The response rate was 20% (16/80). Respondents were
composed of nine gastroenterologists, two oncologists,
two surgeons, one radiotherapist, one methodologist and
one statistician. Ten of these respondents had answered
the first questionnaire.
For each cancer site and stage, final ranking of the end-
points was performed according to the frequency at
which they were chosen as first, second or third most rel-
evant potential surrogates by each participant (for com-
plete detailed results, see additional file 3: Propositions
and rankings of potential surrogate endpoints for overall
survival). In oesophagus cancer, preferred endpoints in
the neoadjuvant setting were DFS, R0 resection and
response (81%, 69%, 44%, respectively). In case of non
operable, non metastatic disease, PFS (69%), response
(63%), DFS (50%) and metastatic PFS (31%) were ranked
number 1, 2 and 3, respectively. In the metastatic setting,
PFS, QoL in association with PFS, and QoL alone were
the best rated endpoints (69%, 63%, 44%, respectively).Methy et al. BMC Cancer 2010, 10:277
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Other endpoints proposed for oesophagus cancer
included metabolic response, ratio involved nodes to
examined nodes and dysphasia-free survival.
In stomach cancer, preferred potential surrogate end-
points in the neoadjuvant setting were DFS (93%), R0
resection (56%) and response (44%). In the metastatic set-
ting, QoL associated with PFS was ranked first (81%), fol-
lowed by PFS alone (75%), response and QoL alone (both
44%).
For small hepatocellular carcinoma (HCC), DFS, PFS,
local control and response were the preferred potential
surrogate endpoints (69%, 44%, 31%, 31%, respectively).
In case of advanced HCC, preferred endpoints were PFS
(88%), response (50%) and QoL (44%). For metastatic dis-
ease, QoL in association with PFS was ranked first (81%),
followed by PFS alone (56%) and QoL alone (31%). Other
endpoints included hospitalisation-free survival, hepato-
cellular function, clinical benefit and alpha-FP kinetic.
In pancreas cancer, best rated endpoints in the neoad-
juvant setting were DFS (88%) and R0-R1 resection. For
non operable tumours, PFS (88%), QoL (50%) and meta-
static PFS (44%) were the best rated endpoints. For meta-
s t a t i c  d is eas e ,  P F S  was  r a n k ed  f i r s t  ( 8 1 % ) ,  f o l l o w ed  b y
symptom-free survival (50%). Other endpoints for pan-
creas cancer included response, hospitalisation-free sur-
vival, CA19-9 decline and pain.
For biliary tract cancer, best rated endpoints in the neo-
adjuvant setting were DFS (81%) and R0 resection (63%).
Figure 2 Participant answers to the question: "The following sentences may characterize a surrogate endpoint. Which one or which ones 
(maximum 3) seem important for you to remember?". Proposition 1: "A surrogate endpoint is a variable known to be a prognostic factor" Propo-
sition 2: "A surrogate endpoint is a variable correlated with overall survival" Proposition 3: "A surrogate endpoint is a biomarker1 that is intended to 
substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemi-
ologic, therapeutic, pathophysiologic, or other scientific evidence" (ref. [3]) 1 A biomarker is "a characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention" Proposition 4: "A sur-
rogate endpoint is an intermediate endpoint, reliably and reproducibly measurable (imaging, biology...), which allows to predict the effect of the treat-
ment on the clinical endpoint" (ref. [13]) Proposition 5: "A surrogate endpoint is a variable which is accepted as primary endpoint in clinical trials by 
medical agencies (e.g. FDA, EMEA, AFSSAPS, etc.)2" 2 FDA, (United State) Food and Drug Administration; EMEA, European Medicines Agency; AFSSAPS, 
Agence Française de Sécurité Sanitaire des Produits de Santé Proposition 6: "A surrogate endpoint is a response variable for which a test of the null 
hypothesis of no relationship to the treatment groups under comparison is also a valid test of the corresponding null hypothesis based on the true 
endpoint" (ref. [14])
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For non operable, non metastatic disease, preferred end-
points were PFS (81%), QoL (63%) and response (56%). In
the metastatic setting, preferred endpoints were PFS,
response and QoL (75%, 56%, 50%, respectively). Icterus-
free survival was among the other suggested endpoints.
For localized digestive lymphoma, preferred endpoints
were DFS and response (69%, 31%, respectively). Other
endpoints included percentage of high-grade transforma-
tion per year and gastrectomy avoidance. In the meta-
static setting, DFS was ranked first (63%). Other
endpoints included response (38%) and time-to-remis-
sion (38%).
For the adjuvant treatment of colon cancer, participants
preferred DFS (93%), specific survival (56%) and QoL
(31%). For the neoadjuvant treatment of rectal cancer,
DFS was ranked first (100%), followed by response, com-
plete resection, sphincter preservation and QoL (69%,
56%, 19%, 6%, respectively). In metastatic colorectal can-
cer, best rated endpoints were PFS (75%), QoL in associa-
tion with PFS, and R0 metastatic resection rate (both
56%). Other endpoints included response, QoL, cumula-
tive time without cytotoxic treatment and maintenance
regimen-free survival.
For non metastatic anal cancer, preferred endpoints
were DFS, response, sphincter preservation rate and
abdominoperitoneal amputation-free survival (69%, 50%,
50%, 31%, respectively for localized disease, and 50%,
31%, 25%, 25%, respectively for locally advanced disease).
In the metastatic setting, PFS was ranked first (69%), fol-
lowed by QoL in association with PFS (56%). Other end-
points included symptom-free survival, response and
QoL.
Discussion
Participants of our survey highlighted key points of the
definition, properties and use of surrogate endpoints for
OS in digestive cancer clinical trials. Because other crite-
ria than OS take part in their therapeutic decisions and
practice, they agreed on the need for validation, to ensure
that surrogate endpoints allow reliable prediction of sur-
vival benefit. A large amount of endpoints was proposed
for surrogacy evaluation. Event-free survival endpoints,
such as DFS and PFS, were preferred to early treatment
e f f e c t  e v a l u a t i o n ,  s u c h  a s  R 0  r e s e c t i o n  a n d  r e s p o n s e .
There was discrepancy about the relevance of studying
QoL as surrogate for OS. However, QoL was often pro-
posed in metastatic stages, in association or not with PFS.
Our panellists were active participants in the field of
oncology trials (investigators, methodologists), therefore
the results of this survey may not fully reflect knowledge
and opinions of other professionals not directly involved
in the conduct of a trial. Indeed, we limited our panel to
FFCD scientific council members and methodologists in
anticancer centres for practical reasons, but also under
the assumption that they would be more committed and
disposed to participate. However, a low proportion of
them fulfilled the questionnaires. One can suppose that
some non-respondents felt not sufficiently comfortable
with this issue. Besides, the parts of the questionnaires
that were asking participants to suggest and classify
potential surrogate endpoints may have best suited clini-
cians than methodologists. Moreover, since a lot of diges-
tive tumour sites and settings were dealt with, the
questionnaires may have appeared heavy-going. A higher
participation rate could have generated more proposi-
tions of potential surrogate endpoints and might have
modified the final sorting. The survey was also per-
formed with an educational goal, to lead people to ques-
tion themselves on the relevance of the endpoints used in
oncology trials. Thus we chose a self-administered ques-
tionnaires approach to allow participants to freely express
their opinion, without being influenced by others.
Respondent answers covered major issues surrounding
surrogacy. The main point concerns the difference with a
prognostic factor. Though most surrogate endpoints are
also prognostic, a prognostic factor is not necessarily a
surrogate [18,19]: "a correlate does not a surrogate make"
[20]. Indeed, even if two endpoints are correlated, treat-
ment effects on them are not necessarily correlated too
and effect on an intermediate variable does not necessar-
Table 1: Advantages and risks or limitations of surrogate endpoints put forward by the participants.
Advantages Risks or limitations
To reduce trial duration
• Accelerate approval and dissemination of effective therapies
• More rapidly pass to another question
Use of non validated surrogates
Generalization of the results to another setting or patient 
population
To decrease the required number of patients Alteration of the validity after therapeutic advances
To decrease the cost of the trial Risk of erroneous conclusion concerning survival (reliability), late 
toxicity not measured
Endpoints not confounded by subsequent lines of treatment
• Better imputability
• Power (sensibility) gain
Limitations regarding the definition and the reproducibility of the 
surrogate endpoint
Relevance of the surrogate endpoint in itself CostMethy et al. BMC Cancer 2010, 10:277
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ily predict the effect on the final endpoint [20]. Half of
our participants related surrogacy with outcomes
accepted as primary efficacy endpoints for the evaluation
of oncology products by medical agencies, such as the US
Food and Drug Administration and the European Agency
for the Evaluation of Medicinal Products. They actually
both may rely on surrogate endpoints for marketing
approvals [21,22]. A well-established  (validated) surro-
gate would be able to support regular approval, whereas a
surrogate "reasonably likely to predict clinical benefit"
might only support accelerated/conditional approvals
[23,24]. Because of the difficulty in establishing reliable
surrogacy, debates still remain around the use of surro-
gate endpoints as definitive efficacy criteria [25,26]. Our
participants underlined some risks and limitations. They
reminded that surrogacy depends upon the disease set-
ting and the class of therapeutic agents and that valida-
tion cannot be extrapolated to another situation without
further investigation. They added that there may still
remain a risk of erroneous conclusion on OS and that
short follow-up does not allow to observe unintended late
adverse events. The established surrogate association
may also alter over time with diagnosis and therapeutic
advances, as discussed for 3-year DFS in adjuvant colon
cancer trials [8,9,27,28].
DFS and PFS have been ones of the preferred candidate
surrogate endpoints, whatever cancer site. This could be
explained by the fact that both have been validated and
used in colorectal cancer trials. DFS, defined as the time
from randomization to the first event of either recurrent
disease or death (second primary tumours not counted as
events) has been validated as surrogate for OS in adjuvant
colon cancer trials [8,9]. PFS, defined as the time from
random assignment to progressive disease or death from
any cause, has been validated in advanced colorectal can-
cer [10,11]. On the contrary, time-to-progression, which
does not include death as an event contrary to PFS, was
shown to be less reliable [10,16]. As for response rate,
while allowing an early evaluation of treatment effect, it
does not allow accurate prediction of OS in colorectal
cancers [6,10,15,16].
DFS and PFS were sometimes both proposed in the
questionnaire for the same disease stage. In accordance
with Delphi guidelines, which advise to keep all partici-
pant propositions from first to second round [12], we let
both endpoints in the second questionnaire. However, it
Figure 3 Participant answers to questions about validation and use of surrogate endpoints.
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is finally unclear regarding the events taken into account.
This raises the preliminary question of the definition of
the survival endpoints, for which a uniform terminology
has been stressed as a main concern to compare trial
results [29]. In digestive oncology, standardization of the
definitions of such endpoints has been carried out for
hepatocellular carcinoma trials [30] and colon cancer tri-
als [31,32]. In order to reach a consensus in oncology tri-
als, a European Delphi survey has been initiated by
French methodologists and statisticians from oncology
centres and from the FFCD, in collaboration with the
European Organisation for Research and Treatment of
Cancer. Secondary objectives of that study are to assess
the influence of the definitions over trial results and to
investigate their surrogacy.
In some situations, OS is no longer a reliable endpoint,
e.g. in advanced colorectal cancer treated in the first line,
mainly because of the increasing availability of effective
agents in the subsequent lines [33]. In such cases, rather
than or before dealing with surrogacy issue, one has to
define the most appropriate clinical efficacy endpoint.
Clinical value to the patient of endpoints other than OS is
thus sometimes questioned. This has been discussed for
PFS in advanced colorectal cancer [25,33] and for DFS in
adjuvant trials, where disease recurrence has high subse-
quent costs, QoL impact and debilitating consequences
[8]. Similarly, in rectal cancer, preoperative chemoradia-
tion has become the standard neoadjuvant treatment
because of a significant benefit with respect to local con-
trol compared with preoperative radiotherapy alone,
though no impact on survival was demonstrated [34,35].
As reminded by Fleming et al. [25], "oncology patients
are interested in achieving clinically meaningful benefi-
cial effects on disease-related symptoms, on ability to
carry out normal activities, and on OS". As a direct mea-
sure of how a patient feels, functions, or survives [3], QoL
is considered as a clinical endpoint, thus allowing QoL
improvement alone to serve as a basis for marketing
approval [36]. By definition, QoL would be additionally
surrogate for OS if treatment effect on QoL predicted a
survival benefit. While our participants were divided
about studying QoL as surrogate for OS in the first round,
QoL was generally well-rated in the second round for
advanced stages. They put forward complementarity
between PFS and QoL by proposing these criteria as a
composite surrogate endpoint for OS. Two thirds of our
Figure 4 Participant answers to questions about quality of life.
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participants declared they considered QoL as the second-
ary endpoint in cancer clinical trials. There is an increas-
ing interest in endpoints such as time to symptomatic
deterioration or time to QoL deterioration. However, the
variability in the definition and analysis of QoL end-
points, including rules about censoring and missing data,
cut-off for QoL decrease, and QoL dimensions, currently
limit surrogacy validation. Nevertheless, simple but well-
validated tools for the measurement of global QoL [37]
could be incorporated into future trials with relative ease
for surrogacy evaluation purpose.
Conclusions
In conclusion, the overall results of our study should help
prioritise the endpoints to be statistically evaluated as
surrogate for OS and highlight original potential alterna-
tive endpoint. As preferred potential surrogates in each
digestive tumour site, event-free survival endpoints
should be first evaluated, with particular interest for QoL
or composite endpoints including QoL in the metastatic
setting.
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